Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 5/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.55 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.53 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.53 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.53 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.53 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1620260 | 1.00 | CYP1A2 (0.67) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| SCHEMBL8464563 | 1.00 | CYP1A2 (0.67) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| SCHEMBL27685617 | 0.98 | CYP1A2 (0.64) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| SCHEMBL28347012 | 0.89 | CYP1A2 (0.75) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| SCHEMBL126171 | 0.83 | CYP1A2 (0.72) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| SCHEMBL269140 | 0.83 | CYP1A2 (0.72) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| SCHEMBL4732055 | 0.83 | CYP1A2 (0.72) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| SCHEMBL11452510 | 0.81 | CYP1A2 (0.69) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| Hydrochloric Acid SCHEMBL27093050 | 0.81 | CYP1A2 (0.69) | CYP1A2MAOBHDAC2CYP1B1CXCL12 | |
| Hydrochloric Acid SCHEMBL5929339 | 0.81 | CYP1A2 (0.69) | CYP1A2MAOBHDAC2CYP1B1CXCL12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586218-A | Chiral octacyclic ether compound and synthetic method and application thereof | 浙江工业大学 | 2024-02-23 | — | — | CN | disclosed |
| US-20190053492-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2019-02-21 | — | — | US | disclosed |
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | disclosed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20140273130-A1 | COMPETITIVE GROWTH AND/OR PRODUCTION ADVANTAGE FOR BUTANOLOGEN MICROORGANISM | BUTAMAX ADVANCED BIOFUELS LLC (US) | 2014-09-18 | — | — | US | disclosed |
| EP-1626963-B1 | Substituted pyrazoline compounds, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2012-08-15 | — | — | EP | disclosed |
| US-8236821-B2 | Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| EP-1743638-A1 | Pharmaceutical formulations of substituted pyrazoline compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | disclosed |
| EP-1743638-A1 | Pharmaceutical formulations of substituted pyrazoline compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | disclosed |
| EP-1718619-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS FOR REDUCING TRIGLYCERIDES IN BLOOD | Laboratorios del Dr. Esteve S.A. (ES) | 2006-11-08 | — | — | EP | disclosed |
| US-20060189658-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DR. ESTEVE S.A. (ES) | 2006-08-24 | — | — | US | disclosed |
| EP-1637522-A1 | Substituted pyrazoline compounds for reducing triglycerides in blood | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-22 | — | — | EP | disclosed |
| EP-1626963-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-22 | — | — | EP | disclosed |
| US-20060020010-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2006-01-26 | — | — | US | disclosed |
| WO-2005077911-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005077909-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS FOR REDUCING TRIGLYCERIDES IN BLOOD | LABORATORIOS DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | disclosed |
| US-6204220-B1 | AS HERBICIDES FOR CONTROLLING UNWANTED VEGETATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2001-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020010-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | PIR, SYMPK, P2RX5 | CYP1A2 110/4885MAOB 798/4885HDAC2 715/4885 |
| US-20190053492-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS PESTICIDES | CHRM1, CHRM2, ACHE | CYP1A2 47/4885MAOB 1165/4885HDAC2 1393/4885 |
| US-20060189658-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | PIR, SYMPK, P2RX5 | CYP1A2 110/4885MAOB 798/4885HDAC2 715/4885 |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | CYP1A2 1700/4885MAOB 989/4885HDAC2 387/4885 |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | CFTR, CHRM3, P2RY1 | CYP1A2 1007/4885MAOB 2275/4885HDAC2 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.